RxDoctor Payments Data

Marc Sizemore

Family · Visalia, CANPI 1043419138

Payments from drug & device makers

$2,939in general payments, 2019–2025

Across 165 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$300
  • Takeda Pharmaceuticals U.S.A., Inc.$297
  • AstraZeneca$276
  • Boehringer Ingelheim$173
  • Pfizer$108
  • plus $675 from 18 others

What the payments were for

  • Food & beverage$2,939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,939 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$119,102
Medicare patients
479
Services billed
1,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide33$53,272
FarxigaDapagliflozin Propanediol15$22,475
EliquisApixaban26$21,493
OzempicSemaglutide19$17,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,040
XareltoRivaroxaban14$11,994
JardianceEmpagliflozin14$8,444
Memantine Hcl14$3,559
Aripiprazole33$2,163
Desvenlafaxine Succinate ErDesvenlafaxine Succinate17$1,593
Levothyroxine Sodium128$1,484
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide38$1,475
Atorvastatin Calcium156$1,381
Rosuvastatin Calcium56$1,347
Gabapentin81$1,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$300$53,27233 claims
AstraZenecaFarxiga$276$22,47515 claims
PfizerEliquis$108$21,49326 claims
Novo NordiskOzempic$47$17,43019 claims
Boehringer IngelheimJardiance$173$8,44414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →